DK1860101T3 - Tartrat salt af isofagomin og fremgangsmåder til anvendelse deraf - Google Patents

Tartrat salt af isofagomin og fremgangsmåder til anvendelse deraf

Info

Publication number
DK1860101T3
DK1860101T3 DK07252109.9T DK07252109T DK1860101T3 DK 1860101 T3 DK1860101 T3 DK 1860101T3 DK 07252109 T DK07252109 T DK 07252109T DK 1860101 T3 DK1860101 T3 DK 1860101T3
Authority
DK
Denmark
Prior art keywords
isophagomine
methods
tartrate salt
salt
gaucher disease
Prior art date
Application number
DK07252109.9T
Other languages
English (en)
Inventor
Benjamin Mugrage
David Palling
Philip J Rybczynski
Kamlesh A Sheth
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Application granted granted Critical
Publication of DK1860101T3 publication Critical patent/DK1860101T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
DK07252109.9T 2006-05-24 2007-05-23 Tartrat salt af isofagomin og fremgangsmåder til anvendelse deraf DK1860101T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80802006P 2006-05-24 2006-05-24
US89071907P 2007-02-20 2007-02-20

Publications (1)

Publication Number Publication Date
DK1860101T3 true DK1860101T3 (da) 2011-07-25

Family

ID=38462442

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07252109.9T DK1860101T3 (da) 2006-05-24 2007-05-23 Tartrat salt af isofagomin og fremgangsmåder til anvendelse deraf

Country Status (14)

Country Link
US (2) US7501439B2 (da)
EP (1) EP1860101B1 (da)
JP (1) JP5292605B2 (da)
AT (1) ATE504570T1 (da)
AU (1) AU2007202359B2 (da)
BR (1) BRPI0706114A2 (da)
CA (1) CA2590122C (da)
DE (1) DE602007013648D1 (da)
DK (1) DK1860101T3 (da)
IL (1) IL183415A (da)
MX (1) MX2007006175A (da)
PL (1) PL1860101T3 (da)
PT (1) PT1860101E (da)
WO (1) WO2007140212A2 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006254796B2 (en) 2005-06-08 2012-08-16 Amicus Therapeutics, Inc. Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes
BRPI0713442A2 (pt) * 2006-06-23 2012-03-06 Amicus Therapeutics, Inc. Método para o tratamento de desrodens neurológicas, pelo aumento da atividade de b-glicocerebrosidase
KR101597499B1 (ko) * 2007-05-22 2016-02-24 아미쿠스 세라퓨틱스, 인코포레이티드 이소파고민과 이의 유도체를 제조하는 새로운 방법
EP2946785B1 (en) 2008-02-12 2018-10-24 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
EP2361089A4 (en) * 2008-11-14 2012-08-22 Parkinson S Inst COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED FUNCTION OF -SYNUCLEINE
CN102686237B (zh) 2009-07-28 2018-10-19 夏尔人类遗传性治疗公司 用于治疗戈谢病的组合物
PT2995306T (pt) * 2009-10-19 2019-03-29 Amicus Therapeutics Inc Novas composições para prevenção e/ou tratamento de disfunções de armazenamento lisossomal
ES2814178T3 (es) 2009-10-19 2021-03-26 Amicus Therapeutics Inc Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central
ES2724531T3 (es) 2011-05-12 2019-09-11 Proteostasis Therapeutics Inc Reguladores de proteostasis
AU2012272815B2 (en) * 2011-06-22 2017-09-07 The General Hospital Corporation Treatment of proteinopathies
JP2015504919A (ja) 2012-01-25 2015-02-16 プロテオステイシス セラピューティクス，インコーポレイテッド プロテアソーム活性を調節する化合物
CN104519905A (zh) 2012-03-02 2015-04-15 夏尔人类遗传性治疗公司 用于治疗iii型戈谢病的组合物和方法
AU2013240486B2 (en) 2012-03-27 2017-10-26 Amicus Therapeutics, Inc. Novel compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system
JP2015512913A (ja) * 2012-03-28 2015-04-30 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ グルコセレブロシダーゼ活性剤として有用なサリチル酸誘導体
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
DE102017103346A1 (de) * 2017-02-17 2018-08-23 Lts Lohmann Therapie-Systeme Ag Strukturierte orodispergierbare Filme
BR112020007820A2 (pt) * 2017-10-26 2020-10-20 Shire Human Genetic Therapies, Inc. formulações compreendendo glucocerebrosidase e isofagomina
CN112585132A (zh) 2018-06-27 2021-03-30 蛋白质平衡治疗股份有限公司 蛋白酶体活性增强化合物
EP3814336A1 (en) 2018-06-27 2021-05-05 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
JP2022530017A (ja) * 2019-04-25 2022-06-27 武田薬品工業株式会社 イソファゴミン塩、その使用方法および製剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844102A (en) 1994-07-07 1998-12-01 University Of Maryland Baltimore County Glycohydrolase inhibitors, their preparation and use thereof
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A

Also Published As

Publication number Publication date
BRPI0706114A2 (pt) 2008-11-18
US7501439B2 (en) 2009-03-10
AU2007202359B2 (en) 2012-02-16
IL183415A0 (en) 2007-09-20
US7863453B2 (en) 2011-01-04
PL1860101T3 (pl) 2011-10-31
CA2590122A1 (en) 2007-11-24
PT1860101E (pt) 2011-07-12
EP1860101A1 (en) 2007-11-28
JP2007314540A (ja) 2007-12-06
MX2007006175A (es) 2009-02-16
US20090176830A1 (en) 2009-07-09
AU2007202359A1 (en) 2007-12-13
WO2007140212A2 (en) 2007-12-06
EP1860101B1 (en) 2011-04-06
US20070281975A1 (en) 2007-12-06
WO2007140212A3 (en) 2008-12-24
IL183415A (en) 2012-03-29
JP5292605B2 (ja) 2013-09-18
CA2590122C (en) 2015-03-31
DE602007013648D1 (de) 2011-05-19
ATE504570T1 (de) 2011-04-15

Similar Documents

Publication Publication Date Title
DK1860101T3 (da) Tartrat salt af isofagomin og fremgangsmåder til anvendelse deraf
ATE532518T1 (de) Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
NO20070470L (no) Sammensetninger og fremgangsmater for behandling av dyslipidemi
ATE445587T1 (de) Verfahren zur herstellung von cinacalcet hydrochlorid kristallform i
DK1704146T3 (da) Stereoisomere forbindelser og fremgangsmåder til behandling af mave-tarm- og centralnervesystemlidelser
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
PL1960379T3 (pl) Pochodne N-(1-alkilo-2-fenyloetylo)-karboksamidu i ich zastosowanie jako fungicydów
EA200702208A1 (ru) Ингибиторы дипептидилпептидазы-iv
DK1720848T3 (da) Derivater af alkylpiperazin- og alkylhomopiperazincarboxylater, fremgangsmåde til fremstilling heraf og anvendelse heraf som inhibitorer af enzymet FAAH
NO20054876D0 (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
ATE530519T1 (de) Cyclobutylaminderivate
ATE447559T1 (de) 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3- carboxamid derivate als mek inhibitoren zur behandlung von hyperproliferativen erkrankungen
DE602006018354D1 (de) Verfahren zur behandlung von abnormalem zellwachstum
DK1901731T3 (da) Niacinreceptoragonister, sammensætninger indeholdende sådanne forbindelser og fremgangsmåder til behandling
DE602006013271D1 (de) Verfahren zur herstellung von 4-(phenoxy-5-methyl-pyrimidin-4-yloxy)piperidin-1-carboxylsäure-derivaten und damit zusammenhängenden verbindungen
NO20081905L (no) Benzotiazolcyklobutylaminderivater og deres anvendelse som histamin-3-reseptorligander
ATE439831T1 (de) Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung
DK1617834T3 (da) Anvendelse af en farmaceutisk sammensætning indeholdende mælkesyre eller lactat og kalium til behandling af hjerneödem eller hjerneskade
UA88481C2 (ru) Донепезила фумарат, пригодный для получения фармацевтических композиций
DK1856063T3 (da) 5-phenyl-pentansyrederivater som matrix- metalloproteinaseinhibitorer til behandlingen af astma og andre sygdomme
DK1641456T3 (da) Gaboxadol til behandling af depression og andre affektive lidelser
EA201001773A1 (ru) Фумаратная соль 4-(3-хлор-2-фторанилино)-7-метокси-6-{[1-(n-метилкарбамоилметил)пиперидин-4-ил]окси}хиназолина
BRPI0519093A2 (pt) mÉtodo para preparaÇço de amlodipina opticamente ativa e composto
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины
DK2067779T3 (da) Tiotropiumsalte, fremgangsmåde til deres fremstilling og lægemiddelformuleringer indeholdende disse